Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

8 Mar 2025

Abstract excerpt

Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by development of antibodies against clotting factor VIII (FVIII). It is characterized by severe spontaneous bleeding and prolonged bleeding after injury, often life-threatening. The therapeutic approach includes hemostatic medication (bypassing agents and recombinant porcine FVIII) to stop acute bleeding, and immunosuppressive therapy (IST) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40057635
DOI: 10.1038/s41375-025-02554-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-CD19 CAR-T cell therapy for acquired hemophilia APMID 40057635Read ↗

Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan.Semantic proximity Read ↗

Acquired hemophilia A: Updated review of evidence and treatment guidance.Semantic proximity Read ↗

CAR-T cell therapy embarks on autoimmune diseaseSemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief reviewSemantic proximity Read ↗

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to BedsideSemantic proximity Read ↗

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global ContextSemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

Fully human CD19-specific chimeric antigen receptors for T-cell therapySemantic proximity Read ↗

Development of inhibitors in hemophilia A: An illustrated reviewSemantic proximity Read ↗

Development of Ingenui-T, a Novel Vein-to-Vein Solution for Rapid Autologous CAR T-Cell Manufacturing Starting From Whole Blood, for the Treatment of Autoimmune DiseasesSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.